Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 17,031 | 21,031 | 10,705 | 10,775 | 13,278 |
| TOTAL | $17,402 | $21,476 | $11,493 | $11,294 | $13,436 |
| Non-Current Assets | |||||
| PPE Net | 10 | 11 | 12 | 7 | 4 |
| TOTAL | $10 | $11 | $12 | $7 | $4 |
| Total Assets | $17,412 | $21,487 | $11,505 | $11,301 | $13,440 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 260 | 435 | 516 | 235 | 427 |
| Accrued Expenses | 690 | 905 | 1,150 | 971 | 843 |
| TOTAL | $950 | $1,340 | $1,666 | $1,206 | $1,270 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $950 | $1,340 | $1,666 | $1,206 | $1,270 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 11,617 | 11,617 | 10,764 | 5,727 | 4,798 |
| Common Shares | 1 | 1 | 1 | N/A | N/A |
| Retained earnings | -159,057 | -155,054 | -152,683 | -150,291 | -148,125 |
| TOTAL | $16,462 | $20,147 | $9,839 | $10,095 | $12,170 |
| Total Liabilities And Equity | $17,412 | $21,487 | $11,505 | $11,301 | $13,440 |